-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
As CureVac N.V. (NASDAQ:CVAC) Drops to US$1.4b Market Cap, Insiders Might Rethink Their €97m Stock Purchase Earlier This Year
As CureVac N.V. (NASDAQ:CVAC) Drops to US$1.4b Market Cap, Insiders Might Rethink Their €97m Stock Purchase Earlier This Year
The recent 22% drop in CureVac N.V.'s (NASDAQ:CVAC) stock could come as a blow to insiders who purchased €97m worth of stock at an average buy price of €16.97 over the past 12 months. Insiders buy with the expectation to see their investments rise in value over a period of time. However, recent losses have rendered their above investment worth €43m which is not ideal.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
Check out our latest analysis for CureVac
CureVac Insider Transactions Over The Last Year
Over the last year, we can see that the biggest insider purchase was by insider Dietmar Hopp for US$97m worth of shares, at about US$16.97 per share. That means that even when the share price was higher than US$7.48 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Dietmar Hopp was the only individual insider to buy during the last year.
The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
NasdaqGM:CVAC Insider Trading Volume September 25th 2022There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).
Insider Ownership Of CureVac
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. CureVac insiders own 9.0% of the company, currently worth about US$126m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
So What Do The CureVac Insider Transactions Indicate?
The fact that there have been no CureVac insider transactions recently certainly doesn't bother us. But insiders have shown more of an appetite for the stock, over the last year. With high insider ownership and encouraging transactions, it seems like CureVac insiders think the business has merit. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. In terms of investment risks, we've identified 2 warning signs with CureVac and understanding these should be part of your investment process.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
最近22%的降幅CureVac N.V.纳斯达克(Kleiner Perkins Caufield&Byers)股票代码:CVAC对在过去12个月中以16.97欧元的平均买入价购买了价值9700万欧元股票的内部人士来说,可能是一个打击。内部人士买入股票的预期是,他们的投资会在一段时间内升值。然而,最近的亏损使他们的上述投资价值达到4300万欧元,这并不理想。
虽然我们永远不会建议投资者完全根据公司董事的所作所为做出决定,但按照逻辑,你应该关注内部人士是在买入还是卖出股票。
查看我们对CureVac的最新分析
CureVac去年的内幕交易
过去一年,我们可以看到,最大的内幕收购是内部人士Dietmar Hopp以每股16.97美元的价格收购了价值9700万美元的股票。这意味着,即使股价高于7.48美元(最近的价格),也有内部人士想要购买股票。尽管他们的观点可能在收购后发生了变化,但这至少表明他们对公司的未来充满信心。我们总是仔细注意内部人士购买股票时支付的价格。一般来说,当内部人士以高于当前价格的价格买入股票时,我们对股票的看法更积极,因为这表明他们认为股票很有价值,即使价格更高。Dietmar Hopp是去年唯一买入的个人内部人士。
下面的图表显示了过去一年的内幕交易(按公司和个人)。如果你想知道到底是谁卖了,卖了多少钱,什么时候卖的,只需点击下面的图表!
NasdaqGM:CVAC内幕交易量2022年9月25日内部人士总是在买入大量股票。因此,如果这适合你的风格,你可以逐一检查每一种库存,或者你可以看看这个免费公司名单。(提示:内部人士一直在买入这些股票)。
CureVac的内部人所有权
另一种测试公司领导人与其他股东之间一致性的方法是看他们拥有多少股份。我认为,如果内部人士持有该公司大量股份,这是一个好兆头。CureVac内部人士持有该公司9.0%的股份,根据最近的股价计算,目前价值约1.26亿美元。我喜欢看到这种程度的内部人持股,因为它增加了管理层考虑股东最佳利益的机会。
那么,CureVac Insider的交易表明了什么?
CureVac最近没有发生内幕交易,这一事实当然不会让我们感到困扰。但在过去一年里,内部人士对该股表现出了更大的兴趣。由于拥有较高的内部人持股和鼓励交易,CureVac内部人士似乎认为这项业务有价值。因此,虽然了解内部人士在买入或卖出方面做了什么是有帮助的,但了解一家特定公司面临的风险也是有帮助的。在投资风险方面,我们已经确定了两个警告信号拥有CureVac并理解这些应该是你投资过程的一部分。
当然了,如果你把目光投向别处,你可能会发现这是一笔很棒的投资。所以让我们来看看这个免费有趣的公司名单。
就本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前负责公开市场交易和私人处置,但不包括衍生品交易。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧